Cellectar Biosciences, Inc. CLRB
We are a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of drugs for the treatment of cancer. Our core objective is to leverage our proprietary phospholipid ether drug conjugate ™ (PDC™) delivery platform to develop PDCs that are designed to specifically target cancer cells and deliver improved efficacy and better safety as a result of fewer off-target effects. We believe that our PDC platform possesses the potential for the discovery and development of the next generation of cancer-targeting treatments, and we plan to develop PDCs both independently and through research and development collaborations.
The Company is primarily focused on the development of its radioconjugate PDC programs, also known as phospholipid radioconjugates or PRCs, designed to provide targeted delivery of a radioisotope directly to cancer cells, while limiting exposure to healthy cells. We believe this profile differentiates our PRCs from many traditional on-market treatments and radiotherapeutics. Our three lead programs are: CLR 121125 (CLR 125), an iodine-125 Auger-emitting program, prepared to enter a clinical trial in 2025; CLR 121225 (CLR 225), an actinium-225 based program; and iopofosine I 131 (iopofosine I 131, or simply iopofosine), a beta-emitting iodine-131 based program which has been studied extensively, as described below. On June 4, 2025, the Company announced that the U.S Food and Drug Administration (the "FDA") granted Breakthrough Therapy Designation for iopofosine I 131, as a radioconjugate monotherapy for the treatment of relapsed/refractory Waldenstrom macroglobulinemia (r/r WM). On October 6, 2025, the Company announced that after a scientific advice procedure, the Scientific Advice Working Party (SAWP) of the European Medicines Agency (EMA) advised that filing for a Conditional Marketing Authorization (CMA) for iopofosine I 131 as a treatment for post - Bruton Tyrosine Kinase inhibitor (BTKi) refractory patients with Waldenstrom macroglobulinemia (WM) could be acceptable for a CMA.
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| R&D | $11.5M | $26.1M | $27.3M | $18.3M | $17.6M | $10.1M | $9.0M | $6.8M | $9.5M | $4.8M |
| SG&A | $11.5M | $25.6M | $11.7M | $10.5M | $6.5M | $5.1M | $5.2M | $4.8M | $4.1M | $4.7M |
| Total operating expenses | $23.0M | $51.8M | $39.0M | $28.8M | $24.1M | $15.3M | $14.2M | $13.3M | $13.6M | $9.4M |
| Operating income | -$23.0M | -$51.8M | -$39.0M | -$28.8M | -$24.1M | -$15.3M | -$14.2M | -$13.3M | -$13.6M | -$9.4M |
| Pre-tax income | -$21.8M | -$44.5M | -$42.8M | -$31.9M | -$24.1M | — | -$14.1M | -$13.2M | -$13.6M | -$6.2M |
| Income tax | — | $66.0K | $60.0K | $60.0K | — | — | $0 | $0 | $0 | $0 |
| Net income | -$21.8M | -$44.6M | -$38.0M | -$31.8M | -$24.1M | -$15.1M | -$14.1M | -$13.2M | -$13.6M | -$6.2M |
| EPS, basic | -8.35 | -36.52 | -3.50 | -4.51 | -4.35 | -0.76 | — | — | — | — |
| EPS, diluted | -8.35 | -41.89 | -3.50 | -4.51 | -4.35 | -1.84 | -1.84 | -5.23 | -10.70 | -2.14 |
| Shares, diluted (wtd. avg.) | 2.6M | 1.2M | 12.2M | 7.1M | 5.6M | 19.8M | — | — | — | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $13.2M | $23.3M | $9.6M | $19.9M | $30.6M | $57.2M | $10.6M | $13.3M | $10.1M | $11.5M |
| Total current assets | $14.0M | $24.3M | $10.5M | $25.3M | $31.4M | $57.9M | $11.4M | $14.0M | $10.5M | $12.2M |
| Property, plant and equipment | $549.4K | $757.1K | $1.1M | $364.8K | $331.1K | $356.0K | $435.1K | $543.3K | $244.7K | $1.4M |
| Goodwill | — | — | — | — | — | — | $0 | $0 | $1.7M | $1.7M |
| Total assets | $15.0M | $25.5M | $12.1M | $25.9M | $32.0M | $58.7M | $12.3M | $15.1M | $12.9M | $15.3M |
| Accounts payable | $1.4M | $4.1M | $5.6M | $2.6M | $4.5M | $1.4M | $1.3M | $612.0K | $933.0K | $1.4M |
| Total current liabilities | $4.7M | $9.4M | $25.4M | $6.5M | $7.4M | $3.6M | $2.8M | $1.6M | $2.1M | $1.6M |
| Total liabilities | $5.1M | $9.8M | $25.9M | $6.6M | $7.5M | $3.9M | $3.2M | $1.8M | $2.1M | $1.8M |
| Retained earnings | -$269.1M | -$247.3M | -$202.8M | -$140.1M | -$134.4M | -$126.8M | -$111.7M | -$97.6M | -$84.3M | -$70.8M |
| Total equity | $8.5M | $14.3M | -$15.2M | $8.2M | $29.1M | $54.8M | $9.1M | $13.3M | $10.8M | $13.5M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$23.1M | -$47.6M | -$32.4M | -$25.2M | -$22.6M | -$13.9M | -$11.7M | -$11.4M | -$11.0M | -$8.3M |
| Depreciation and amortisation | $213.6K | $291.7K | $192.4K | $148.4K | $149.9K | $141.5K | $132.8K | $82.3K | $1.5M | $356.7K |
| Stock-based compensation | $2.3M | $4.3M | $2.4M | $1.5M | $1.1M | $467.5K | $866.8K | $721.2K | $758.8K | $529.2K |
| Capital expenditure | $5.9K | $104.2K | $864.0K | $226.0K | $141.4K | $62.4K | $24.5K | $385.0K | $346.7K | $72.3K |
| Investing cash flow | -$5.9K | -$104.2K | -$864.0K | -$226.0K | -$141.4K | -$62.4K | -$24.5K | -$330.0K | -$346.7K | -$72.3K |
| Financing cash flow | $13.0M | $61.4M | $22.9M | $9.6M | $1.2M | $60.5M | $9.0M | $15.0M | $9.9M | $15.9M |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001104659-26-067626.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — | — | — |
| Net income | -$6.2M | -$13.6M | -$13.2M | -$14.1M | -$15.1M | -$24.1M | -$31.8M | -$38.0M | -$44.6M | -$21.8M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Officer or director change Someone at the top arrived or left. The item covers everything from a board retirement to a chief executive being removed, and only the filing itself says which. Item 5.02
- Shareholder vote The results of the annual meeting or a special vote. Item 5.07
- Officer or director change Item 5.02
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Results announced Item 2.02
- Material agreement signed Item 1.01
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |